Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Illumina, Inc., a San Diego, California-headquartered biotechnology firm, announced that its chief financial officer, Joydeep Goswani, is leaving. His departure was confirmed on Tuesday, April 9.
New Executives at the HQ
The company said it has appointed Ankur Dhingra as its new CFO. Goswani's successor is revealed to be an executive at Summit Therapeutics. He will be leaving the company, where he most recently served in the same chief financial role, to join Illumina.
Aside from Dhingra, Illumina is also welcoming Jakob Wedel, who has been named the new chief strategy and corporate development officer. At any rate, Reuters reported that the new CFO worked at CareDx, a medical test manufacturer, before being hired at Summit Therapeutics. He also spent almost 18 years at Agilent Technologies and has decades of experience in the life science business sector.
Relocation and Date of Leadership Appointments
Meanwhile, Illumina's newly appointed senior executives, Dhingra and Wedel, are set to be transferred to San Diego for their respective roles. The two will start working at the company on April 15. On the other hand, Goswami will remain in the company until June 30 and officially leave on July 1.
"I am proud of the talent joining our management team as we work to deliver on Illumina's mission to improve human health by unlocking the power of the genome," Illumina's chief executive officer, Jacob Thaysen, said in a press release. "Ankur brings deep financial expertise, investor and leadership experience, and industry knowledge to Illumina's CFO role, and Jakob has keen insights gained from 25 years in strategy leadership roles with global consulting firms."
The CEO added, "We are grateful to Joydeep for his many contributions to Illumina over more than four years, and for most recently leading these two key functions. Joydeep will continue with us for several weeks to support a smooth leadership transition."
Photo by: Illumina Press Release
